Tech Company Financing Transactions
Precision BioSciences Funding Round
On 6/27/2018, Precision BioSciences announced $110 million in Series B investment from ArrowMark Partners, Adage Capital Management and Agent Capital.
Transaction Overview
Company Name
Announced On
6/27/2018
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series B
Investors
Proceeds Purpose
Precision plans to utilize the proceeds from this financing to accelerate and expand its product portfolio.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
302 East Pettigrew St. Dibrell Building A-100
Durham, NC 27701
USA
Durham, NC 27701
USA
Phone
Website
Email Address
Overview
The Precision BioSciences (Nasdaq: DTIL) mission is to translate the world's most powerful genome editing technology into greatly needed products throughout the life sciences.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Kane
Chief Scientific Officer
Derek Jantz
Vice President
Clayton Beard
VP - Bus. Development
Drew Applefield
VP - Bus. Development
Michael Dombeck
VP - Engineering
Victor Bartsevich
VP - Finance
Abid Ansari
VP - Marketing
Heather King
VP - Operations
Sinu Bhandaru
VP - Regulatory Affairs
Marcia Gaido
Browse more venture capital transactions:
Prev: 6/27/2018: Aclima venture capital transaction
Next: 6/28/2018: Carisma Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. All VC database entries reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs